Press Release - November 2, 2017
Heidelberg, Germany, November 1, 2017 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that the Company will present clinical and preclinical data on its immune cell engagers AFM13 and AFM26 at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2017 in Atlanta, Georgia.
Title: A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1
Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after
Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study (Abstract #1522)
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
Date: Saturday, December 9, 2017, 5:30 PM – 7:30 PM Eastern Time
Location: Hall A2 (Georgia World Congress Center)
Title: AFM26 – Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of
Multiple Myeloma (Abstract #3082)
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Date: Sunday, December 10, 2017, 6:00 PM – 8:00 PM Eastern Time
Location: Hall A2 (Georgia World Congress Center)
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required, email hidden; JavaScript is required